Prothena
Prothena’s Alzheimer’s Trial Hit by High ARIA-E Rates, Resulting in ‘Non-Competitive’ Profile
Prothena; PRX012; Alzheimer’s disease; ARIA-E; brain swelling; phase 1 trial; non-competitive profile; amyloid beta antibody; ASCENT clinical program; subcutaneous administration
Roche Advances Prasinezumab Into Phase III Trials for Parkinson’s Despite Mixed Phase II Results
Roche; prasinezumab; Parkinson’s disease; Phase III trial; clinical trials; alpha-synuclein antibody; Prothena; PADOVA study; PASADENA study; biomarker; disease-modifying treatment
Prothena Halts Drug and Plans Major Layoffs After Second Rare Disease Trial Failure
Prothena; birtamimab; AL amyloidosis; Phase III trial; drug failure; layoffs; biotech; spending cuts; business options
Roche’s Prasinezumab Fails Primary Endpoint in Phase 2b Parkinson’s Trial, Shows Promising Trends
Roche, Prothena, Parkinson’s disease, prasinezumab, alpha-synuclein, phase 2b trial, PADOVA study